Comparison study of pharmacokinetic parameters of donafenib and sorafenib in the first-line treatment of advanced hepatocellular carcinoma

Donafenib in Liver Cancer Research Collaboration Group; QIN Shukui; BI Feng; BAI Yuxian; SHENG Zelin

doi:10.3969/j.issn.1009-0460.2022.06.001

Home>Articles>Comparison study of pharmacokinetic parameters of donafenib and sorafenib in the first-line treatment of advanced hepatocellular carcinoma

DOI: 10.3969/j.issn.1009-0460.2022.06.001

Comparison study of pharmacokinetic parameters of donafenib and sorafenib in the first-line treatment of advanced hepatocellular carcinoma

Donafenib in Liver Cancer Research Collaboration Group

QIN Shukui

BI Feng

BAI Yuxian

SHENG Zelin

Machine-generated Keywords：

Publication Date：2022-06-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：7( 481-487 )

Chinese Clinical Oncology

ISTICPKU

ISSN：1009-0460

Year, Vol.(Issue)：2022,27(6)